Page 25 - Read Online

Page 8 of 9 Ashdown. J Cancer Metastasis Treat 2022;8:6 https://dx.doi.org/10.20517/2394-4722.2022.01

malignant tumours. Autoimmun Rev 2017;16:1270-81. DOI PubMed
21. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science 2015;348:69-74. DOI PubMed
22. Piersma SJ, Welters MJ, van der Burg SH. Tumor-specific regulatory T cells in cancer patients. Hum Immunol 2008;69:241-9. DOI
PubMed
23. Chauhan R, Trivedi V. Inflammatory markers in cancer: potential resources. Front Biosci (Schol Ed) 2020;12:1-24. DOI PubMed
24. Hui L, Chen Y. Tumor microenvironment: sanctuary of the devil. Cancer Lett 2015;368:7-13. DOI PubMed
25. Anderson NM, Simon MC. The tumor microenvironment. Curr Biol 2020;30:R921-5. DOI PubMed PMC
26. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med 2013;19:1423-37. DOI PubMed
PMC
27. Yuan R, Li S, Geng H, et al. Reversing the polarization of tumor-associated macrophages inhibits tumor metastasis. Int
Immunopharmacol 2017;49:30-7. DOI PubMed
28. Poh AR, Ernst M. Targeting macrophages in cancer: from bench to bedside. Front Oncol 2018;8:49. DOI PubMed PMC
29. Kumar V, Patel S, Tcyganov E, Gabrilovich DI. The nature of myeloid-derived suppressor cells in the tumor microenvironment.
Trends Immunol 2016;37:208-20. DOI PubMed PMC
30. Berraondo P, Sanmamed MF, Ochoa MC, et al. Cytokines in clinical cancer immunotherapy. Br J Cancer 2019;120:6-15. DOI
PubMed PMC
31. Li L, Yu R, Cai T, et al. Effects of immune cells and cytokines on inflammation and immunosuppression in the tumor
microenvironment. Int Immunopharmacol 2020;88:106939. DOI PubMed
+
32. Hoekstra ME, Vijver SV, Schumacher TN. Modulation of the tumor micro-environment by CD8 T cell-derived cytokines. Curr Opin
Immunol 2021;69:65-71. DOI PubMed PMC
33. Arenas-Ramirez N, Woytschak J, Boyman O. Interleukin-2: biology, design and application. Trends Immunol 2015;36:763-77. DOI
PubMed
34. Zaidi MR. The interferon-gamma paradox in cancer. J Interferon Cytokine Res 2019;39:30-8. DOI PubMed PMC
35. Montfort A, Colacios C, Levade T, Andrieu-abadie N, Meyer N, Ségui B. The TNF paradox in cancer progression and
immunotherapy. Front Immunol 2019;10:1818. DOI PubMed PMC
36. Coventry BJ, Ashdown ML. The 20th anniversary of interleukin-2 therapy: bimodal role explaining longstanding random induction of
complete clinical responses. Cancer Manag Res 2012;4:215-21. DOI PubMed PMC
37. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2
receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol
1995;155:1151-64. PubMed
+
38. Kamada T, Togashi Y, Tay C, et al. PD-1 regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. Proc
Natl Acad Sci U S A 2019;116:9999-10008. DOI PubMed PMC
39. Marangoni F, Zhakyp A, Corsini M, et al. Expansion of tumor-associated Treg cells upon disruption of a CTLA-4-dependent feedback
loop. Cell 2021;184:3998-4015.e19. DOI PubMed PMC
40. Gratz IK, Rosenblum MD, Maurano MM, et al. Cutting edge: self-antigen controls the balance between effector and regulatory T cells
in peripheral tissues. J Immunol 2014;192:1351-5. DOI PubMed PMC
41. Pinheiro DF, Szenes-Nagy AB, Maurano MM, et al. Cutting edge: tissue antigen expression levels fine-tune T cell differentiation
decisions in vivo. J Immunol 2020;205:2577-82. DOI PubMed PMC
42. Busse D, de la Rosa M, Hobiger K, et al. Competing feedback loops shape IL-2 signaling between helper and regulatory T
lymphocytes in cellular microenvironments. Proc Natl Acad Sci U S A 2010;107:3058-63. DOI PubMed PMC
43. McNally A, Hill GR, Sparwasser T, Thomas R, Steptoe RJ. CD4+CD25+ regulatory T cells control CD8+ T-cell effector
differentiation by modulating IL-2 homeostasis. Proc Natl Acad Sci U S A 2011;108:7529-34. DOI PubMed PMC
44. Challa DK, Mi W, Lo ST, Ober RJ, Ward ES. Antigen dynamics govern the induction of CD4(+) T cell tolerance during
autoimmunity. J Autoimmun 2016;72:84-94. DOI PubMed
45. Pradeu T, Vivier E. The discontinuity theory of immunity. Sci Immunol 2016;1:AAG0479. DOI PubMed PMC
46. Pradeu T, Cooper EL. The danger theory: 20 years later. Front Immunol 2012;3:287. DOI PubMed PMC
47. Kareva I. Immune suppression in pregnancy and cancer: parallels and insights. Transl Oncol 2020;13:100759. DOI PubMed PMC
48. Bruno V, Corrado G, Baci D, et al. Endometrial cancer immune escape mechanisms: let us learn from the fetal-maternal interface.
Front Oncol 2020;10:156. DOI PubMed PMC
49. Nottke A. Taming the cycle: how does the pill work? Available from: https://sitn.hms.harvard.edu/flash/2008/issue40/ [Last accessed
on 25 Feb 2022].
50. Flemming A. Cancer: tumour-specific ablation of Treg cells induces anticancer response. Nat Rev Drug Discov 2016;15:676-7. DOI
PubMed
51. Ohue Y, Nishikawa H. Regulatory T (Treg) cells in cancer: can Treg cells be a new therapeutic target? Cancer Sci 2019;110:2080-9.
DOI PubMed PMC
52. Boyman O, Kolios AG, Raeber ME. Modulation of T cell responses by IL-2 and IL-2 complexes. Clin Exp Rheumatol 2015;33:S54-7.
PubMed
53. Tran E, Robbins PF, Rosenberg SA. ‘Final common pathway’ of human cancer immunotherapy: targeting random somatic mutations.
Nat Immunol 2017;18:255-62. DOI PubMed PMC
54. Shimizu K, Iyoda T, Okada M, Yamasaki S, Fujii SI. Immune suppression and reversal of the suppressive tumor microenvironment.
Int Immunol 2018;30:445-54. DOI PubMed